Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW493838 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| GW493838 | DRUG | - |
Inclusion criteria (subjects must meet all of the following criteria in order to be eligible for this study): * Females of non-child-bearing potential * diagnosis of peripheral neuropathic pain as a result of: postherpetic neuralgia (PHN) from shingles for at least 3 months duration OR focal neurop...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE2 | LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA |
| Dogwood Therapeutics Inc | DWTX | 1 | PHASE2 | Halneuron |
| Sangamo Therapeutics, Inc. | SGMO | 1 | PHASE1 | ST-503 |
| Boston Scientific Corporation | BSX | 1 | N/A | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | N/A | Undisclosed |
GW493838 is an investigational small molecule being studied for the treatment of neuropathic pain. It is a peripheral neuropathic pain therapy that has been evaluated in clinical trials. The drug is not approved and remains in clinical development.
GW493838 is an adenosine A1 agonist. It works by activating the adenosine A1 receptor, which is involved in pain signaling pathways. This mechanism is being studied for its potential to relieve neuropathic pain.
GW493838 is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical research on this drug for neuropathic pain.
GW493838 is in Phase 2 clinical development. It has completed a Phase 2 trial, and it is still an investigational drug. It has not been approved by regulatory authorities for any use.
GW493838 has been studied in one completed Phase 2 clinical trial, identified as NCT00376454. This trial, titled 'The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain,' enrolled 113 participants in the United States. The trial was randomized and double-blind.